Policy / Pricing A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma BioPharma DiveA series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health.Policy / PricingRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health. Policy / PricingRead full story Post navigation Previous: Agios mulls early FDA filing for sickle cell therapyNext: FDA, after turbulent year, leaves drugmakers guessing on its direction Related Stories Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026 Policy / Pricing EU agrees plan to tackle essential medicine shortages pharminent May 12, 2026 Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) pharminent May 12, 2026
